Synergy Pharmaceuticals to Initiate Phase 2 Study of SP-333 for Opioid-Induced Constipation

Synergy Pharmaceuticals Inc. SGYP today announced plans to move forward this quarter with SP-333, its proprietary next-generation guanylate cyclase-C (GC-C) agonist, into a phase 2 study for the treatment of opioid-induced constipation (OIC). “The start of this trial represents the ongoing progress being made in the clinical development of our novel GC-C agonist platform in multiple gastrointestinal indications,” said Dr. Gary S. Jacob, President and Chief Executive Officer of Synergy Pharmaceuticals Inc. “We recognize a significant market opportunity for new OIC drug candidates and believe SP-333 has excellent potential to address the unmet medical needs of these patients. We look forward to evaluating the potential role of SP-333 for OIC as part of our See full press release